Carol Cornman, Vice President of the Childhood Brain Tumor Foundation, brings her leadership skills to the organization. Each year family, friends, and supporters join Carol and her daughters in celebrating the memory of her husband Geoff Cornman, a victim of a brain tumor many years ago. Carol brings to the Childhood Brain Tumor Foundation her years of experience as one of the owners of PRISM and Vice President of Business Development. With over 18 years of experience in delivery, business development, sales, operations and executive leadership, she maintains the ability to build and execute strategic business plans and teams that are centered on quality and deliver maximum results. A focus on quality is what allows Carol to provide services which exceed customer and employee expectations. Her consultant creativity coupled with her epic business ability ensures that she is called on to master superior success with any challenge faced.

Born in New Jersey, Dr. Burger grew up in Chicago and attended Oberlin College in Ohio. His medical training began at Northwestern University Medical School in Chicago and completed at Duke University Medical Center, Durham NC after a combined residency in anatomic pathology and fellowship in neuropathology. He remained at Duke as a faculty member for twenty years until he accepted a position of Professor of Pathology, Oncology, and Neurosurgery at the Johns Hopkins University School of Medicine in Baltimore, MD.

Dr. Burger has had a special interest in brain and spinal cord tumors in children, being a reviewer of select protocols for the Children’s Oncology Group (COG), and before that for CNS tumor protocols of the Pediatric Oncology Group. Dr. Burger maintains an active consult practice as reviewer of CNS tumors, and maintains close relationships with oncology programs and pathology departments at many pediatric hospitals. While not in a position to give clinical advice, he is always willing to speak with parents about pathological issues.

Dr. Warren received her B.S., in medical technology in 1982 and her M.D., from Tufts University School of Medicine in 1990. She completed a residency in pediatrics at Children's National Medical Center, followed by a fellowship in pediatric oncology at the National Cancer Institute. She is board certified in pediatric hematology/oncology. Her research interests include performance of clinical trials, particularly in children with tumors of the central nervous system, non-invasive evaluation/imaging of the brain, and neurotoxicity resulting from tumors and their treatment.

Cancer of the central nervous system (CNS) is the leading cause of death from solid tumors in the pediatric population. For some types of CNS malignancies, such as diffuse intrinsic pontine glioma (DIPG) and recurrent malignant glioma, no significant improvement in survival has been demonstrated over the past three decades. The approach to treatment has not changed substantially, despite increasing knowledge of tumor biology. The goal of Dr. Warren's research is to establish new therapeutic paradigms based on pharmacokinetic and biologic rationale to improve both survival and quality of life for children with CNS tumors.

Dr. Warren's strategy entails a multifaceted approach.

  1. Experimental therapeutics and extensive noninvasive analysis of individual patients, including multiparametric imaging
  2. Utilization of a nonhuman primate model to study CNS pharmacology of agents and alternate delivery methods
  3. Identification of intratumor genomic alterations that encode potentially druggable targets

Click here to view Dr. Warren's full biography.

Associate Professor Pediatrics
Director, Pediatric Neuro-Oncology Program

Following his training in pediatrics, pediatric hematology-oncology and neuro-oncology, Dr. MacDonald has built a career that encompasses clinical, basic and translational research of childhood brain tumors. He has received continuous NIH-sponsored funding support for his research efforts for the past 9 years, which has focused on identification of molecular therapeutic targets of perdiatric brain tumors. Having pioneered the use of microarray technology for the study of pediatric medulloblastoma and astrocytoma, and discovering that the platelet-derived growth factor receptor (PDGFR) is active and over-produced by metastatic tumors and tumors demonstrating more malignant characteristics, respectively, he is now working to translate these and other novel findings to innovative treatments for children with brain tumors.

Before joining the Aflac Cancer Center to direct the Pediatric Neuro-Oncology Program in September 2009, Dr. MacDonald served as the Clinical Director of Neuro-oncology at Children’s National Medical Center from 1998-2009 and served as Chair of Infant Brain Tumors for the NIH-sponsored Pediatric Brain Tumor Consortium (PBTC) as well as Co-Chair of the PBTC Biology and Angiogenesis Committees since the group’s inception in 1999. In addition to serving on numerous clinical trial committees within PBTC and the Children’s Oncology Group, most prominently as Principal Investigator of the completed Phase I and currently ongoing Phase II study of cilengitide, which he helped to develop from bench-to-bedside, Dr. MacDonald was the institutional Principal Investigator for over 26 clinical trials conducted through PBTC.

One of his additional passions is training the next generation of pediatric scientists, and over the past 10 years, he has mentored 14 students, from undergraduate to graduate and medical, and 9 post-doctoral fellows, the majority of which are now currently conducting oncology research of their own.

Click here to view Dr. MacDonald's full biography.

Mrs. Young is the President and one of the Founding members of the Childhood Brain Tumor Foundation, an all-volunteer nonprofit organization founded in 1994 dedicated to supporting research, heightening awareness, and improving the quality of life for children affected by brain tumors. Her dedication to the cause comes from many cancer-related challenges her family has faced. At the age of 17 she lost her father to brain cancer. Her son is a long-term brain tumor survivor. She has taken these tragedies and turned her efforts to helping others in this situation through patient advocacy, awareness, and support for childhood brain tumor victims and their families.

Mrs. Young has served as a patient advocate, board member, and in various other roles in a number of related organizations, including:

  • Patient Advocate Steering Committee (2011 to present)
  • Patient Advocate Reviewer – Department of Defense, Peer Review Cancer Related Program (PRCRP) (2009 to present)
  • Patient Advocate – Children’s Oncology Group (COG) Developmental Therapeutics Steering Committee (2007 to present)
  • Patient Advocate – National Cancer Institute (NCI) Clinical Imaging Steering Committee (2011 to present)
  • Consumer Advocate in Research and Related Activities – NCI Special Emphasis Panels and Specialized Panel of Research Excellence (2000 to present)
  • Member, Central Institutional Review Board, Pediatrics (2009 to present)
  • Member, NCI Safety Monitoring Committee (2007 to present)
  • Member, American Brain Coalition (2009 to present)
  • Patient Advocate--National Cancer Institute Sub-Committee D (2004 to 2006)
  • Committee Member - Pediatric Brain Tumor Consortium Parent/Family Committee (2004 to present)
  • Board Member - Pediatric Brain Tumor Consoritum Foundation (2007 to present)
  • North American Brain Tumor Coalition (2001 to 2008, various roles, Secretary, Vice Chair, and last as Co-Chair)
  • National Institutes of Health/National Cancer Institute--Brain Tumor Progress Review Group, participant (2000)


University of Maryland, BA, Arts/Psychology
International Symposium on Pediatric Neuro-Oncology, 1998 to Present
Society for Neuro-Oncology, 2000 – 2008, 2012 to present


MCPS Educational Foundation, Inc. - Program Administrator (part-time)

Paul Graham Fisher is Professor of Neurology and Pediatrics, and by courtesy, Neurosurgery and Human Biology; the Beirne Family Professor of Pediatric Neuro-Oncology; and Division Chief of Child Neurology at Stanford University. He is also the Director of the Center for Brain and Behavior.

After starting his career on the faculty at Johns Hopkins, he was recruited back to Stanford in 1997 to Stanford, where he started the pediatric brain tumor program at Lucile Packard Children’s Hospital. That childhood brain tumor program is now the largest comprehensive childhood brain tumor center for research and care in the Western United States, and a member of the NCI’s Pediatric Brain Tumor Consortium. Professor Fisher is a nationally sought teacher, and in 2007 received both the 44th Annual Arthur L. Bloomfield Award and 39th Annual Henry J. Kaiser Family Foundation Award for excellence in teaching at the Stanford School of Medicine. At Stanford he also directs the undergraduate class “Cancer Epidemiology” in Human Biology. He is the Child Neurology Residency Director at the School of Medicine, Chair of the Section for Neurology in the American Academy of Pediatrics, and editorial board member for The Journal of Pediatrics and Journal of Neuro-Oncology, and previously Journal of Clinical Oncology. He is also a member of the Board of Directors for the National Brain Tumor Society and the Advisory Board for the Greater Bay Area Make-A-Wish Foundation.

His research focuses on epidemiology, therapy, and late effects of childhood brain tumors, and he has authored over 120 publications on brain tumors and other neurology topics. His epidemiologic work explores biologic underpinnings of childhood brain tumors, particularly medulloblastoma, ependymoma, and germ cell tumors.

His personal interests are his wife and three children, along with skiing, travel, gardening, bad golf, and anything baseball.

Academic History:

B.A., with Distinction, Stanford University, 1985
M.D., University of California, San Francisco, 1989
M.H.S., Johns Hopkins University, 1995

Paul G. Fisher, M.D. is a member of the Childhood Brain Tumor Foundation’s Medical/Scientific Advisory.

Brian R. Rood, MD is an Associate Professor of Pediatrics in the Center for Cancer and Blood Disorders at Children’s National Medical Center whose primary clinical focus is pediatric neuro-oncology. Dr. Rood joined the faculty of Children’s National in 2002 after completing a fellowship in Pediatric Hematology/Oncology as well as a research fellowship in the molecular biology of brain tumors, both at Children’s National and Children’s Research Institute. Dr. Rood received an undergraduate degree in English Literature from the Pennsylvania State University and his medical degree from Jefferson Medical College. He completed his training in General Pediatrics at the University of Vermont.

Dr. Rood is the Director of Clinical Neuro-oncology at Children’s and cares for brain tumor patients on the inpatient oncology ward and in the outpatient clinic. He is co-PI with Dr. Roger Packer of the Pediatric Brain Tumor Consortium clinical trial program at Children’s. He also runs an active NIH funded molecular biology lab in the Center for Cancer and Immunology Research of the Children’s Research Institute. His lab is working to elucidate the mechanisms whereby the loss of the tumor suppressor gene HIC1 leads to the genesis of brain tumors. He is also investigating the proteome of cerebrospinal fluid in order to discover a protein marker for the presence of pediatric brain tumors.

Click here to view Dr. Rood's full biography.

Dr. Roger J. Packer, MD is Senior Vice-President, Center for Neuroscience and Behavioral Medicine, and Chairman of Neurology at the Children’s National Medical Center (CNMC). He is Director of both the Brain Tumor Institute and the Daniel and Jennifer Gilbert Neurofibromatosis Institute. Dr. Packer’s present academic titles include Professor of Neurology and Pediatrics at The George Washington University and Clinical Professor of Neurosurgery at the University of Virginia in Charlottesville, Virginia. Prior to coming to CNMC, Dr. Packer was Director of the Brain Tumor Program and Professor of Neurology and Pediatrics at the Children’s Hospital of Philadelphia, University of Pennsylvania. He is an active participant at the National Institutes of Health and has a contract with the combined NCI/NINDS Neuro-Oncology Program to provide neuro-oncological clinical expertise.

Throughout his career, Dr. Packer has been heavily involved in clinical and applied basic science research. His clinical research has touched on various aspects of adult and child neurology and neuro-oncology, including adult and pediatric brain tumors, neurofibromatosis type 1, the neurologic aspects of childhood neurogenetic diseases, and multiple other topics in general child neurology. Much of his research has focused on the development and performance of clinical trials for adults and children with neurologic and neuropsychiatric disorders, and he has received peer-reviewed grant support for this research. Many of the clinical trials in Neurofibromatosis and brain tumors are translational, bringing advances from the bench to the bedside expeditiously.

Presently, Dr. Packer is principal investigator at Children’s National for the Pediatric Brain Tumor Consortium (PBTC), formed under the auspices of the National Cancer Institute; Chairman of the PBTC Low-Grade Glioma Committee; Group Chair of the newly-formed Neurofibromatosis Clinical Trials Consortium; and he is Chair of the Medulloblastoma Committee of the Children’s Oncology Group. He has worked closely with the NCI and NINDS, and has served on multiple committees setting the directions for neurologic clinical and basic science research for the future. He headed the efforts in pediatrics for the program review, held by the NCI and NINDS, for brain tumors. Much of Dr. Packer’s clinical research has been translational in nature. He has been part of studies evaluating the molecular genetics of childhood and adult neurologic diseases and has also coordinated the first gene therapy study for children with malignant brain tumors in the United States. The majority of the studies now being coordinated by Dr. Packer are studies evaluating innovative agents aimed at the molecular underpinnings of neurologic disease. He has published over 275 original articles and 250 reviews and chapters.

Click here to view Dr. Packer's full biography.

Dr. Bruce practices neurosurgery in Washington, District of Columbia. He is one of the pioneers of modern pediatric neurosurgery. His specialties include cranial base surgery, craniofacial anomalies, epilepsy, and brain tumors.

Education: University Of Edinburgh, College Of Medicine & Veterinary Medicine Edinburgh, United Kingdom
Graduated: 1966

Vice Chair for Research, Department of Pediatrics, Baylor College of Medicine

Susan M. Blaney, M.D., a Professor and Vice Chair for Research in the Department of Pediatrics at Baylor College of Medicine, has served as the Chair for Developmental Therapeutics in the COG since 2008. She previously served as the Vice Chair for the COG Phase I Consortium (2000-2008) and the POG Phase 1 Sub-Committee (1996-2000).

Dr. Blaney has more than 20 years experience in the design, development, and implementation of all aspects of NCI-sponsored and industry-sponsored new agent clinical trials for children with refractory/recurrent cancer. She also has extensive experience in the design and evaluation of preclinical in vitro and pharmacology studies of anti-cancer agents. Dr. Blaney has authored more than 75 publications specifically related to the clinical development of anticancer agents for children and has numerous other publications related to the preclinical development or pharmacology of anticancer therapies. She has served on NCI Special Emphasis panels for new agent development, FDA advisory groups and industry advisory panels. As a member of the Investigational Drug Steering Committee Dr. Blaney has served on its coordinating and pharmacology sub-committees.

Thanks to Our Sponsors